NCT00111891已完成2 期
A Dose Ranging Study to Evaluate the Tolerability of MK0524 (Niacin (+) Laropiprant) and Its Effects on Niacin-Induced Acute Flushing in Lipid Clinic Patients and/or Normal Healthy Subjects
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 575
- 主要终点
- Acute cutaneous symptoms induced by niacin for 7 days.
研究概览
简要总结
This is a 3-week trial in normal healthy or lipid clinic patients studying a novel approach to treating dyslipidemia.
详细描述
The duration of treatment is 7 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 25 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Males and females (ages 25-75)
排除标准
- •A condition which, in the opinion of the investigator, might pose a risk to the patient or interfere with participating in the study
结局指标
主要结局
Acute cutaneous symptoms induced by niacin for 7 days.
时间窗: 7 days
次要结局
- Tolerability(7 days)
研究者
相似试验
招募中
4 期
Letermovir for Secondary Prophylaxis in Solid Organ Transplant RecipientsCytomegalovirus InfectionsInfection in Solid Organ Transplant RecipientsNeutropeniaAntiviral ToxicityNCT05626530Tufts Medical Center25
已完成
1 期
Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male VolunteersHealthyNCT00629733Rovi Pharmaceuticals Laboratories12
已完成
2 期
Dose-Ranging Study in Treatment Naive Type 2 Diabetes Mellitus(T2DM)Diabetes Mellitus, Type 2NCT00500331GlaxoSmithKline334
终止
3 期
An Investigational Drug Co-Administered With Insulin in Patients With Type 2 Diabetes (0478-065)Type 2 Diabetes MellitusNCT00130806Merck Sharp & Dohme LLC600
终止
2 期
Efficacy and Safety of Lu AA34893 in Patients With Major Depressive DisorderMajor Depressive DisorderNCT00766870H. Lundbeck A/S35